FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914403907> ?p ?o ?g. }

• W2914403907 endingPage "800" @default.
• W2914403907 startingPage "792" @default.
• W2914403907 abstract "To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA) arm was included to allow a direct comparison with an approved therapy.An exploratory phase II, multicenter, randomized, vehicle-controlled clinical trial, double-masked between CyclASol and vehicle with an open-label comparator.Two hundred and seven eligible patients with a history of dry eye disease were randomized 1:1:1:1 to 1 of 4 treatment arms (CyclASol 0.05%, n = 51; CyclASol 0.1%, n = 51; vehicle, n = 52, and Restasis, n = 53).After a 2-week run-in period with twice-daily dosing of Systane Balance (Alcon, Fort Worth, TX), patients were randomized to the respective treatment arm and dosed twice daily for 16 weeks.The study was set up to explore efficacy on a number of sign and symptom end points including total and subregion corneal fluorescein staining, conjunctival staining, visual analog scale (VAS) for dry eye symptoms VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire.CyclASol showed a consistent reduction in corneal and conjunctival staining compared with both vehicle and Restasis over the 16-week treatment period, with an early onset of effect (at day 14). A mixed-effects model-based approach demonstrated that the CyclASol drug effect was statistically significant over vehicle (total corneal staining P < 0.1, central corneal staining P < 0.001, conjunctival staining P < 0.01). This model-based analysis suggests a significant CyclASol effect for OSDI as symptom parameter (P < 0.01). The numbers of ocular adverse events were low in all treatment groups.CyclASol showed efficacy, safety, and tolerability at 2 concentrations in moderate-to-severe DED. In a direct head-to-head against open-label Restasis, CyclASol was found to have an earlier onset of action, as early as after 2 weeks of treatment, in relieving the signs of DED, as measured by corneal and conjunctival staining. The central region of the cornea, an important area for visual function in dry eye sufferers, was shown to have the most benefit from treatment. Excellent safety, tolerability, and comfort profile supports this new CsA formulation as having a positive benefit-to-risk ratio." @default.
• W2914403907 created "2019-02-21" @default.
• W2914403907 creator A5010870123 @default.
• W2914403907 creator A5012925663 @default.
• W2914403907 creator A5014064088 @default.
• W2914403907 creator A5014387622 @default.
• W2914403907 creator A5014939337 @default.
• W2914403907 creator A5019216993 @default.
• W2914403907 creator A5039185760 @default.
• W2914403907 creator A5069849547 @default.
• W2914403907 creator A5083670329 @default.
• W2914403907 creator A5087676704 @default.
• W2914403907 date "2019-06-01" @default.
• W2914403907 modified "2023-10-10" @default.
• W2914403907 title "A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease" @default.
• W2914403907 cites W1413023120 @default.
• W2914403907 cites W1523354060 @default.
• W2914403907 cites W1964372510 @default.
• W2914403907 cites W1971052157 @default.
• W2914403907 cites W1977593833 @default.
• W2914403907 cites W2019761152 @default.
• W2914403907 cites W2054186928 @default.
• W2914403907 cites W2056795722 @default.
• W2914403907 cites W2070610048 @default.
• W2914403907 cites W2087723398 @default.
• W2914403907 cites W2091630088 @default.
• W2914403907 cites W2093545788 @default.
• W2914403907 cites W2115345791 @default.
• W2914403907 cites W2162065037 @default.
• W2914403907 cites W2317457397 @default.
• W2914403907 cites W2318533725 @default.
• W2914403907 cites W2381631717 @default.
• W2914403907 cites W2481777962 @default.
• W2914403907 cites W2512928733 @default.
• W2914403907 cites W2574040535 @default.
• W2914403907 cites W2600375002 @default.
• W2914403907 cites W2784031181 @default.
• W2914403907 doi "https://doi.org/10.1016/j.ophtha.2019.01.024" @default.
• W2914403907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8554539" @default.
• W2914403907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30703441" @default.
• W2914403907 hasPublicationYear "2019" @default.
• W2914403907 type Work @default.
• W2914403907 sameAs 2914403907 @default.
• W2914403907 citedByCount "41" @default.
• W2914403907 countsByYear W29144039072020 @default.
• W2914403907 countsByYear W29144039072021 @default.
• W2914403907 countsByYear W29144039072022 @default.
• W2914403907 countsByYear W29144039072023 @default.
• W2914403907 crossrefType "journal-article" @default.
• W2914403907 hasAuthorship W2914403907A5010870123 @default.
• W2914403907 hasAuthorship W2914403907A5012925663 @default.
• W2914403907 hasAuthorship W2914403907A5014064088 @default.
• W2914403907 hasAuthorship W2914403907A5014387622 @default.
• W2914403907 hasAuthorship W2914403907A5014939337 @default.
• W2914403907 hasAuthorship W2914403907A5019216993 @default.
• W2914403907 hasAuthorship W2914403907A5039185760 @default.
• W2914403907 hasAuthorship W2914403907A5069849547 @default.
• W2914403907 hasAuthorship W2914403907A5083670329 @default.
• W2914403907 hasAuthorship W2914403907A5087676704 @default.
• W2914403907 hasBestOaLocation W29144039071 @default.
• W2914403907 hasConcept C118487528 @default.
• W2914403907 hasConcept C126322002 @default.
• W2914403907 hasConcept C141071460 @default.
• W2914403907 hasConcept C14184104 @default.
• W2914403907 hasConcept C168563851 @default.
• W2914403907 hasConcept C197934379 @default.
• W2914403907 hasConcept C2777288759 @default.
• W2914403907 hasConcept C2778375690 @default.
• W2914403907 hasConcept C71924100 @default.
• W2914403907 hasConceptScore W2914403907C118487528 @default.
• W2914403907 hasConceptScore W2914403907C126322002 @default.
• W2914403907 hasConceptScore W2914403907C141071460 @default.
• W2914403907 hasConceptScore W2914403907C14184104 @default.
• W2914403907 hasConceptScore W2914403907C168563851 @default.
• W2914403907 hasConceptScore W2914403907C197934379 @default.
• W2914403907 hasConceptScore W2914403907C2777288759 @default.
• W2914403907 hasConceptScore W2914403907C2778375690 @default.
• W2914403907 hasConceptScore W2914403907C71924100 @default.
• W2914403907 hasIssue "6" @default.
• W2914403907 hasLocation W29144039071 @default.
• W2914403907 hasLocation W29144039072 @default.
• W2914403907 hasLocation W29144039073 @default.
• W2914403907 hasLocation W29144039074 @default.
• W2914403907 hasOpenAccess W2914403907 @default.
• W2914403907 hasPrimaryLocation W29144039071 @default.
• W2914403907 hasRelatedWork W1979235597 @default.
• W2914403907 hasRelatedWork W2050480145 @default.
• W2914403907 hasRelatedWork W2068849886 @default.
• W2914403907 hasRelatedWork W2151341625 @default.
• W2914403907 hasRelatedWork W2358624079 @default.
• W2914403907 hasRelatedWork W2775663577 @default.
• W2914403907 hasRelatedWork W3048696992 @default.
• W2914403907 hasRelatedWork W4200597295 @default.
• W2914403907 hasRelatedWork W4229014694 @default.
• W2914403907 hasRelatedWork W1962564742 @default.
• W2914403907 hasVolume "126" @default.
• W2914403907 isParatext "false" @default.
• W2914403907 isRetracted "false" @default.

• next